Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors

Journal of Heart and Lung Transplantation

Volumn 30, Issue 3, 2011, Pages 326-331

  De Denus, Simon ^a,b   Zakrzewski, Marcin ^a   Barhdadi, Amina ^b   Leblanc, Marie Hlne ^c   Racine, Normand ^b   Blanger, Franois ^a   Carrier, Michel ^b   Ducharme, Anique ^b   Dub, Marie Pierre ^b   Turgeon, Jacques ^a   White, Michel ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS;

ADULT; ARTICLE; FEMALE; FOLLOW UP; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HAPLOTYPE; HEART GRAFT; HEART TRANSPLANTATION; HOSPITAL DISCHARGE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 79551687411     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2010.09.015     Document Type: Article

References (39)

1. J.A. Kobashigawa, J. Patel, and H. Furukawa Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients J Heart Lung Transplant 25 2006 434 439
2. M. White, H. Haddad, and M.H. Leblanc Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion J Heart Lung Transplant 24 2005 798 809
3. J.R. Rubel, E.L. Milford, and D.B. McKay Renal insufficiency and end-stage renal disease in the heart transplant population J Heart Lung Transplant 23 2004 289 300
4. A.O. Ojo, P.J. Held, and F.K. Port Chronic renal failure after transplantation of a nonrenal organ N Engl J Med 349 2003 931 940
5. J. Lindenfeld, R.L. Page II, and R. Zolty Drug therapy in the heart transplant recipient: Part III: common medical problems Circulation 111 2005 113 117
6. T. van Gelder, A.H. Balk, and R. Zietse Renal insufficiency after heart transplantation: a case-control study Nephrol Dial Transplant 13 1998 2322 2326 (Pubitemid 28416560)
7. M.R. Vossler, H. Ni, and W. Toy Pre-operative renal function predicts development of chronic renal insufficiency after orthotopic heart transplantation J Heart Lung Transplant 21 2002 874 881
8. D.O. Taylor, L.B. Edwards, and M.M. Boucek Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report2007 J Heart Lung Transplant 26 2007 769 781
9. H. Ross, P. Hendry, and A. Dipchand 2001 Canadian Cardiovascular Society Consensus Conference on cardiac transplantation Can J Cardiol 19 2003 620 654
10. M.F. Hebert, A.L. Dowling, and C. Gierwatowski Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors Pharmacogenetics 13 2003 661 674
11. I.A. Hauser, E. Schaeffeler, and S. Gauer ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation J Am Soc Nephrol 16 2005 1501 1511
12. D.R. Kuypers, H. de Jonge, and M. Naesens CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients Clin Pharmacol Ther 82 2007 711 725
13. J.B. Barnard, S. Richardson, and S. Sheldon The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection Transplantation 82 2006 1677 1682
14. H. Zheng, S. Webber, and A. Zeevi Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms Am J Transplant 3 2003 477 483
15. M. Schwab, M. Eichelbaum, and M.F. Fromm Genetic polymorphisms of the human MDR1 drug transporter Annu Rev Pharmacol Toxicol 43 2003 285 307 (Pubitemid 37372643)
16. S. Masuda, and K. Inui An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients Pharmacol Ther 112 2006 184 198
17. Y. Dai, K. Iwanaga, and Y.S. Lin In vitro metabolism of cyclosporine A by human kidney CYP3A5 Biochem Pharmacol 68 2004 1889 1902
18. R.C. Givens, Y.S. Lin, and A.L. Dowling CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults J Appl Physiol 95 2003 1297 1300
19. B.D. Haehner, J.C. Gorski, and M. Vandenbranden Bimodal distribution of renal cytochrome P450 3A activity in humans Mol Pharmacol 50 1996 52 59
20. M.S. Joy, V. Nickeleit, and S.L. Hogan Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein Pharmacotherapy 25 2005 779 789
21. M.J. Koziolek, R. Riess, and H. Geiger Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients Kidney Int 60 2001 156 166
22. R.G. del Moral, M. Andujar, and C. Ramirez Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits Am J Pathol 151 1997 1705 1714
23. R.G. Del Moral, A. Olmo, and A. Osuna Role of P-glycoprotein in chronic cyclosporine nephrotoxicity and its relationship to intrarenal angiotensin II deposits Transplant Proc 30 1998 2014 2016
24. M.S. Joy, S.L. Hogan, and B.D. Thompson Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity Nephrol Dial Transplant 22 2007 1963 1968
25. I. Cascorbi, T. Gerloff, and A. Johne Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects Clin Pharmacol Ther 69 2001 169 174
26. R.H. van Schaik, I.P. van der Heiden, and J.N. van den Anker CYP3A5 variant allele frequencies in Dutch Caucasians Clin Chem 48 2002 1668 1671
27. A.S. Levey, J.P. Bosch, and J.B. Lewis A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470
28. D.W. Johnson, H.J. Saunders, and F.J. Johnson Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells: roles of insulin-like growth factor I, transforming growth factor beta1, and platelet-derived growth factor J Pharmacol Exp Ther 289 1999 535 542
29. C. Ramirez, A. Olmo, and F. O'Valle Role of intrarenal endothelin 1, endothelin 3, and angiotensin II expression in chronic cyclosporin A nephrotoxicity in rats Exp Nephrol 8 2000 161 172
30. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet;49:141-75.
31. B. Klauke, A. Wirth, and A. Zittermann No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation J Heart Lung Transplant 27 2008 741 745
32. S. Hoffmeyer, O. Burk, and O. von Richter Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 2000 3473 3478
33. M. Schaefer, I. Roots, and T. Gerloff In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms Pharmacogenet Genom 16 2006 855 861
34. Y. Kurata, I. Ieiri, and M. Kimura Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein Clin Pharmacol Ther 72 2002 209 219
35. B. Chowbay, H. Li, and M. David Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression Br J Clin Pharmacol 60 2005 159 171
36. M. Goto, S. Masuda, and T. Kiuchi CYP3A5 (*)1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation Pharmacogenetics 14 2004 471 478
37. N. Tsuchiya, S. Satoh, and H. Tada Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplantation 78 2004 1182 1187
38. A.B. Taegtmeyer, J.B. Breen, and J. Smith ATP-binding cassette subfamily B member 1 polymorphisms do not determine cyclosporin exposure, acute rejection or nephrotoxicity after heart transplantation Transplantation 89 2010 75 82
39. J.B. van der Net, J. van Etten, and M. Yazdanpanah Gene-load score of the renin-angiotensin-aldosterone system is associated with coronary heart disease in familial hypercholesterolaemia Eur Heart J 29 2008 1370 1376